Parents delivering a baby in an American hospital this week will, for the first time in more than three decades, be asked to make a decision rather than receive a recommendation about the hepatitis B vaccine. The federal default is gone, and national data show newborn vaccination rates were already falling before it went away.
The Centers for Disease Control and Prevention adopted shared clinical decision-making for the hepatitis B birth dose on Dec. 16, 2025, following an 8-to-3 vote by its vaccine advisory committee 11 days earlier. The change applies only to infants born to mothers who test negative for hepatitis B. For those whose mothers test positive or whose status is unknown, the birth dose plus immune globulin within 12 hours remains recommended with no change.
What did not change is the evidence. Every major independent review conducted since the policy shift has found the birth dose safe and no benefit to delaying it.
The Coverage Numbers Behind the Policy
Birth dose vaccination was already declining before the vote. A JAMA analysis of more than 12.4 million newborns found rates rose from 67.5 percent in early 2017 to 83.5 percent by February 2023, then fell to 73.2 percent by August 2025, as summarized in pediatric trade coverage. The investigators found no single explanation for the reversal. Hepatitis B vaccination was then moved to shared clinical decision-making alongside several other vaccines in the January 2026 update to the childhood immunization schedule.
Separate national research points to why the birth dose matters beyond the first day. A national cohort study published in JAMA Network Open, drawing on more than 1.1 million children in the Vaccine Safety Datalink, found that among children who received the birth dose, 97.6 percent completed the full three-dose series by 18 months. Among the 18.8 percent who missed it, three-dose coverage by 18 months fell from 73.2 percent for children born in 2014 to 55.3 percent for those born in 2023.
That is the practical mechanism most parents never hear about. The birth dose is not only protection on day one. It is the anchor that keeps the rest of the series on schedule.
The Findings of the Independent Reviews
The most comprehensive independent assessment was published in Pediatrics in May 2026 by researchers from the Vaccine Integrity Project at the University of Minnesota's Center for Infectious Disease Research and Policy. The team assessed more than 400 studies and reports, reviewing four decades of research since the first hepatitis B vaccine was licensed.
It found no serious short-term or long-term adverse events or deaths attributable to newborn hepatitis B vaccination. It found no improvement in safety or effectiveness from delaying the first dose, and no evidence supporting routine post-vaccination antibody testing to guide completion of the series.
Angela Ulrich, the infectious disease epidemiologist who helped lead the review, told Medscape the team "did not identify any new evidence" raising a safety concern about the birth dose.
The clinical stakes on the other side are well documented. Infection acquired around the time of birth becomes chronic in roughly 90 percent of cases, compared with a small fraction of adult infections. The birth dose alone reduces perinatal transmission by roughly 70 percent, and the full series with immune globulin does substantially better. Since the universal recommendation was adopted in 1991, pediatric infections in the United States have fallen by more than 95 percent, and infant infections have been nearly eliminated.
The American Academy of Pediatrics continues to recommend the birth dose within 24 hours of delivery, and pediatricians have said they are already seeing more parents decline.
The Screening Gap Parents Are Not Told About
The policy rests on maternal screening being accurate and available. That is where clinicians have raised the sharpest concern.
Prenatal hepatitis B screening is not universal in practice. Some pregnancies involve no prenatal care, some results are not transmitted to the delivery hospital, and a mother can acquire hepatitis B after her screening test. The birth dose historically functioned as a backstop for exactly those failures.
Under the previous default, a screening error was survivable because the baby was vaccinated regardless. Under shared decision-making, a screening error combined with a decision to defer removes both layers at once. That is a small probability applied to a serious and largely irreversible outcome.
Coverage and cost are not the barrier. The CDC has said in a fact sheet on the change that the vaccine remains covered through the Vaccines for Children Program, Medicaid, the Children's Health Insurance Program, Medicare, and federal marketplace plans. Parents who want the birth dose can request it, and it will be provided.
The Conversation to Have Before Delivery
Parents can raise this at a prenatal visit rather than in a delivery room. Useful questions include whether the hepatitis B screening result is on file at the delivering hospital, what the hospital's default practice is now, and whether the pediatric practice follows the CDC schedule or the American Academy of Pediatrics schedule, since the two now differ on this point.
Families who defer should ask specifically when the first dose will be given and how it will be tracked, because the series completion data suggest that is where protection is most often lost. The CDC suggests no earlier than two months if the birth dose is deferred.
Nothing here constitutes medical advice for an individual pregnancy. Parents with questions about their own screening results, risk factors or a partner's status should raise them with an obstetrician or pediatrician.
The advisory committee has not scheduled further action on hepatitis B, and no federal reversal has been proposed. Several state health departments, including New York's, continue to recommend a birth dose for every newborn independent of the federal schedule. MedicalDaily will report further coverage data as it is published.
Key Questions Answered
What changed in the federal recommendation? The CDC adopted shared clinical decision-making for the hepatitis B birth dose in December 2025, for infants born to mothers who test negative. Parents and clinicians now decide together rather than following a universal default.
Does this apply to every newborn? No. Infants born to mothers who test positive for hepatitis B or whose status is unknown are still recommended to receive the vaccine plus immune globulin within 12 hours of birth.
Has any new safety evidence emerged? No. A review of more than 400 studies and reports published in Pediatrics found no serious adverse events or deaths attributable to newborn vaccination and no benefit from delaying the first dose.
Why does timing matter if the series continues later? Infection acquired around birth becomes chronic in roughly 90 percent of cases. National data also show children who miss the birth dose are far less likely to complete the three-dose series by 18 months.
Is the vaccine still covered by insurance? Yes. The CDC has said coverage continues through the Vaccines for Children Program, Medicaid, the Children's Health Insurance Program, Medicare and federal marketplace plans.
Can parents still request the birth dose? Yes. Shared clinical decision-making means the choice belongs to parents and clinicians together. The American Academy of Pediatrics continues to recommend it within 24 hours of birth.
What should parents ask before delivery? Whether the hepatitis B screening result is on file at the delivering hospital, what the hospital's current default is, and which schedule the pediatric practice follows.
